Technical Analysis for ADVM - Adverum Biotechnologies, Inc.

Grade Last Price % Change Price Change
F 3.6 -0.55% -0.02
ADVM closed down 0.55 percent on Friday, May 14, 2021, on 89 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
Earnings due: May 26
*** please verify all earnings dates ***

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down
Historical ADVM trend table...

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 0.00%
Narrow Range Bar Range Contraction 0.00%
NR7 Range Contraction 0.00%
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Narrow Range Bar Range Contraction -0.55%
Wide Bands Range Expansion -0.55%
Oversold Stochastic Weakness -0.55%
Shooting Star Candlestick Bearish -2.70%
Older End-of-Day Signals for ADVM ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Possible Inside Day 2 days ago
Possible NR7 2 days ago
Rose Above 10 DMA 2 days ago
Down 1% 2 days ago
10 DMA Resistance 2 days ago
View Earlier Intraday Alerts

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Adverum Biotechnologies, Inc. Description

Adverum Biotechnologies, Inc., a gene therapy company, engages in discovering and developing novel medicines that offer therapeutic benefit to patients suffering from chronic or debilitating disease. It primary focuses on developing AVA-101, which is in a Phase IIa trial for the treatment of wet age-related macular degeneration (AMD). The company is also developing AVA-201, a product candidate for the prevention of wet AMD; AVA-311 that is in preclinical studies for the treatment of juvenile X-linked retinoschisis, a rare genetic disease of the retina with no approved therapy; and AVA-322 and AVA-323 for the treatment of color vision deficiency. Avalanche Biotechnologies, Inc. has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize gene therapy products. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was founded in 2006 and is headquartered in Menlo Park, California.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Disease Gene Therapy Macular Degeneration Related Macular Degeneration Genetic Disease Retina Wet Age Related Macular Degeneration Rare Genetic Disease Gene Therapy Of The Human Retina Gene Therapy Products Regeneron Adverum Biotechnologies Retinoschisis

Is ADVM a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 26.98
52 Week Low 3.46
Average Volume 2,507,010
200-Day Moving Average 11.67
50-Day Moving Average 8.46
20-Day Moving Average 6.03
10-Day Moving Average 3.67
Average True Range 0.59
ADX 45.32
+DI 13.11
-DI 44.79
Chandelier Exit (Long, 3 ATRs ) 8.55
Chandelier Exit (Short, 3 ATRs ) 5.24
Upper Bollinger Band 11.75
Lower Bollinger Band 0.31
Percent B (%b) 0.29
BandWidth 189.77
MACD Line -1.65
MACD Signal Line -1.55
MACD Histogram -0.0958
Fundamentals Value
Market Cap 350.39 Million
Num Shares 97.3 Million
EPS -1.05
Price-to-Earnings (P/E) Ratio -3.44
Price-to-Sales 3419.85
Price-to-Book 2.96
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.82
Resistance 3 (R3) 3.84 3.78 3.78
Resistance 2 (R2) 3.78 3.72 3.77 3.77
Resistance 1 (R1) 3.69 3.69 3.66 3.67 3.76
Pivot Point 3.64 3.64 3.62 3.63 3.64
Support 1 (S1) 3.55 3.58 3.52 3.53 3.44
Support 2 (S2) 3.49 3.55 3.48 3.43
Support 3 (S3) 3.40 3.49 3.42
Support 4 (S4) 3.38